Cases & Deals

GlycoVaxyn builds bioconjugate vaccine patent portfolio

Clients GlycoVaxyn AG

Jones Day represents GlycoVaxyn AG in developing its patent portfolio and prosecution strategies relating to next-generation bioconjugate vaccines, including methods for production of the vaccines using in vivo systems.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.